Standard Operating Procedure for Market Entry Risk Assessment for New Countries
| Department | Regulatory Affairs |
| SOP No. | RA/2026/651 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 10/04/2026 |
| Effective Date | 10/04/2026 |
| Review Date | 10/04/2028 |
Purpose
This Standard Operating Procedure (SOP) defines a systematic approach to assess risks associated with the market entry of pharmaceutical products into new countries. It aims to ensure that regulatory, quality, compliance, and operational risks are identified, evaluated, and mitigated to support informed decision-making and secure regulatory approvals in alignment with company policies and global regulatory requirements.
Scope
This SOP applies to all regulatory affairs personnel and associated cross-functional teams involved in product registration and market entry activities for new countries. It covers risk assessment related to regulatory submission, compliance with local regulations, labeling, product specifications, supply chain considerations, and any market-specific legal or quality requirements. This SOP excludes post-approval pharmacovigilance and commercial launch processes.
Responsibilities
The following functional roles are responsible for executing and supporting the market entry risk assessment:
- Regulatory Affairs Team – preparation, compilation, and submission of risk assessment reports.
- Quality Assurance – verification of compliance with quality standards and control measures.
- Regulatory Compliance – ensuring assessment adheres to local regulatory frameworks and company policies.
- Regulatory Affairs Manager – review and approval of risk assessment documentation.
- Cross-functional stakeholders (e.g., Supply Chain, Manufacturing, Legal) – provision of relevant data and risk inputs.
Accountability
The Head of Regulatory Affairs is accountable for the implementation, maintenance, compliance, periodic review, and continuous effectiveness of this SOP. Accountability includes escalation of unresolved risks to senior management and ensuring all market entry risk assessments are conducted according to stipulated timelines and compliance obligations.
Procedure
1. Preparation:
a. Identify the new country targeted for product registration and market entry.
b. Gather all relevant regulatory, legal, quality, and commercial information pertaining to the new country, including local guidelines, registration timelines, product requirements, and import/export regulations.
2. Risk Identification:
a. List potential risks related to regulatory approval delays, dossier deficiencies, labeling noncompliance, stability requirements, supply chain interruptions, import restrictions, and quality deviations.
b. Engage cross-functional teams to identify operational, legal, and compliance risks impacting market entry.
3. Risk Analysis and Evaluation:
a. Assess the likelihood and impact of each identified risk using a standardized risk matrix (e.g., low, medium, high severity).
b. Document the rationale for risk ratings with supporting data and references.
4. Risk Mitigation Planning:
a. Define specific mitigation actions such as additional data generation, revised labeling, enhanced quality testing, or regulatory consultations.
b. Assign responsibility and timelines for implementation of mitigation strategies.
5. Review and Approval:
a. Compile the risk assessment report including identified risks, ratings, mitigation plans, and impact analysis.
b. Submit the report to Regulatory Affairs Manager for detailed review and approval.
6. Documentation and Record Retention:
a. Maintain all risk assessment documentation, communications, supporting data, and approval records in the designated regulatory quality system.
b. Ensure documents are controlled and retrievable per company document control standards.
7. Monitoring and Periodic Review:
a. Conduct periodic reviews of the risk assessment prior to submission milestones or regulatory interactions to update risk status or mitigation effectiveness.
b. Escalate unresolved issues or new risks to senior management for decision making.
8. Deviations and Corrective Actions:
a. Document any deviations from the risk assessment process or unexpected regulatory outcomes.
b. Initiate corrective and preventive actions and document outcomes as per quality management procedures.
This procedure ensures controlled and consistent assessment of market entry risks, supporting regulatory compliance and business strategy for new country launches.
Abbreviations
RA – Regulatory Affairs
QA – Quality Assurance
GMP – Good Manufacturing Practice
SOP – Standard Operating Procedure
CAPA – Corrective and Preventive Action
Documents
- Market Entry Risk Assessment Report Template (Annexure-1)
- Risk Mitigation Action Plan Form (Annexure-2)
- Regulatory Requirements Checklist for New Countries (Annexure-3)
References
ICH Q9 Quality Risk Management; Applicable local regulatory agency guidelines; Company Quality Management System (QMS) policies; International GMP standards; Regional pharmacopoeias; WHO guidelines on product registration; Relevant international trade and import/export laws.
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Market Entry Risk Assessment Report Template
Purpose: To systematically document identified risks, their analysis, and overall impact regarding the market entry of a product into a new country.
| Risk ID | Description of Risk | Likelihood | Impact | Risk Rating | Mitigation Summary | Responsible Department |
|---|---|---|---|---|---|---|
| 1 | Delay in regulatory dossier approval due to missing stability data | Medium | High | High | Conduct additional stability studies and submit interim data | Regulatory Affairs |
| 2 | Noncompliance with local labeling language requirements | Low | Medium | Medium | Engage local experts to review and revise labeling content before submission | Regulatory Affairs |
| 3 | Import restrictions delaying product shipment | Medium | Medium | Medium | Coordinate with supply chain for early clearance and documentation | Supply Chain |
Annexure-2: Risk Mitigation Action Plan Form
Purpose: To outline specific corrective or preventive actions to reduce or eliminate identified market entry risks with assigned responsibilities and timelines.
| Action ID | Risk ID | Action Description | Owner | Due Date | Status |
|---|---|---|---|---|---|
| A1 | 1 | Complete stability data generation by local lab | Quality Control | 30/05/2026 | In Progress |
| A2 | 2 | Translate and localize labeling as per country guidelines | Regulatory Affairs | 15/05/2026 | Not Started |
| A3 | 3 | Confirm customs clearance documentation in advance | Supply Chain | 20/05/2026 | Not Started |
Annexure-3: Regulatory Requirements Checklist for New Countries
Purpose: To ensure all country-specific regulatory requirements are identified and addressed prior to submission.
| Requirement | Description | Applicable (Y/N) | Notes |
|---|---|---|---|
| Marketing Authorization Application (MAA) | Complete dossier submission as per country template | Y | Follow local agency format |
| Labeling Requirements | Language, content, and format compliance | Y | Requires local translation and approval |
| Pharmacovigilance Commitment | Local PV system and reporting timelines | Y | PV agreements may be required |
| Stability Data | Minimum shelf life and storage condition data | Y | Stability study per local guidelines mandatory |
| Import License | Permission for product importation prior to launch | Y | Must be obtained before shipment |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 10/04/2026 | 1.0 | Initial issue | New SOP creation |